Bharat Immunolog, a company in the Pharmaceuticals industry, reported revenue of ₹7.65 crore and a net loss of ₹3.88 crore for the March 2023 quarter.
Bharat Immunolog (BSE: BIBCL) closed at ₹9.00 on 20 Nov 2026, down 55.3% over the past year. Its market capitalisation is ₹39 crore.
Incorporated in 1989, Bharat Immunological and Biologicals Corporation Ltd manufactures biotechnology-based pharmaceuticals.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.